Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas.
albumin-bilirubin grade
hepatocellular carcinoma
real-time tumor-tracking radiotherapy
stereotactic body radiotherapy
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
07
04
2021
received:
22
01
2021
accepted:
17
04
2021
pubmed:
25
4
2021
medline:
25
4
2021
entrez:
24
4
2021
Statut:
ppublish
Résumé
To report the outcomes of stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinoma patients. From January 2005 to July 2018, 63 patients with 74 lesions with a maximum diameter ≤52 mm were treated by stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. No patient with a Child-Pugh Score ≥9 was included, and 85.6% had a score of 5 or 6. Using the biological effective dose (BED) with an α/β ratio of 10 (BED With a median follow-up period of 24.6 months (range 0.9-118.4 months), the 1-year and 2-year OS rates were 86.8% (95% confidence interval [95% CI] 75.8-93.3) and 71.1% (57.8-81.6), respectively. The 2-year OS was 89.6% in patients with the baseline modified albumin-bilirubin (mALBI) grade =1, and 61.7% in patients with grade ≥2a. In the multivariate analysis, the mALBI grade (=1 vs. ≥2a) was a significant factor for OS (p = 0.028, 95% CI 1.11-6.18). The 1-year and 2-year local control rates were 100% (100-100%) and 92.0% (77.5-97.5%). The local control rates were significantly higher in the BED This retrospective study of stereotactic body radiotherapy using real-time tumor-tracking radiotherapy for hepatocellular carcinoma showed favorable outcomes with lower incidence of toxicities, especially in patients treated with BED
Types de publication
Journal Article
Langues
eng
Pagination
870-879Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP16K10379
Organisme : Japan Society for the Promotion of Science
ID : JP18H02758
Informations de copyright
© 2021 The Japan Society of Hepatology.
Références
Park JC, Park SH, Kim JH, Yoon SM, Song SY, Liu Z, et al. Liver motion during cone beam computed tomography guided stereotactic body radiation therapy. Med Phys. 2012;39:6431-42.
Tsai Y-L, Wu C-J, Shaw S, Yu P-C, Nien H-H, Lui LT. Quantitative analysis of respiration-induced motion of each liver segment with helical computed tomography and 4-dimensional computed tomography. Radiat Oncol. 2018;13:59.
Lock MI, Klein J, Chung HT, Herman JM, Kim EY, Small W, et al. Strategies to tackle the challenges of external beam radiotherapy for liver tumors. World J Gastroenterol Hepatol Endosc. 2017;9:645-56.
Crane CH, Koay EJ. Solutions that enable ablative radiotherapy for large liver tumors: fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance. Cancer. 2016;122:1974-86.
Shirato H, Shimizu S, Shimizu T, Nishioka T, Miyasaka K. Real-time tumour-tracking radiotherapy. Lancet. 1999;353:1331-2.
Shirato H, Shimizu S, Kunieda T, Kitamura K, van Herk M, Kagei K, et al. Physical aspects of a real-time tumor-tracking system for gated radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48:1187-95.
Taguchi H, Sakuhara Y, Hige S, Kitamura K, Osaka Y, Abo D, et al. Intercepting radiotherapy using a real-time tumor-tracking radiotherapy system for highly selected patients with hepatocellular carcinoma unresectable with other modalities. Int J Radiat Oncol Biol Phys. 2007;69:376-80.
Shimizu S, Nishioka K, Suzuki R, Shinohara N, Maruyama S, Abe T, et al. Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system. Radiat Oncol. 2014;9:118.
Onimaru R, Fujino M, Yamazaki K, Onodera Y, Taguchi H, Katoh N, et al. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:374-81.
Katoh N, Onimaru R, Sakuhara Y, Abo D, Shimizu S, Taguchi H, et al. Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother Oncol. 2008;87:418-24.
Katoh N, Soda I, Tamamura H, Takahashi S, Uchinami Y, Ishiyama H, et al. Clinical outcomes of stage I and IIA non- small cell lung cancer patients treated with stereotactic body radiotherapy using a real- time tumor-tracking radiotherapy system. Radiat Oncol. 2017;12:1-10.
Inoue T, Katoh N, Onimaru R, Shimizu S, Tsuchiya K, Suzuki R, et al. Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer. Radiat Oncol. 2013;8:69.
Hanazawa H, Takahashi S, Shiinoki T, Park SC, Yuasa Y, Koike M, et al. Clinical assessment of coiled fiducial markers as internal surrogates for hepatocellular carcinomas during gated stereotactic body radiotherapy with a real-time tumor-tracking system. Radiother Oncol. 2017;123:43-8.
Morita R, Abo D, Sakuhara Y, Soyama T, Katoh N, Miyamoto N, et al. Percutaneous insertion of hepatic fiducial true-spherical markers for real-time adaptive radiotherapy. Minim Invasive Ther Allied Technol. 2019:29(6):334-43.
Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76:S94-S100.
Kitamura K, Shirato H, Shimizu S, Shinohara N, Harabayashi T, Shimizu T, et al. Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT). Radiother Oncol. 2002;62:275-81.
Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:052-60.
Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6:325-36.
Chapman TR, Bowen SR, Schaub SK, Yeung RH, Kwan SW, Park JO, et al. Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. Pract Rad Oncol. 2018;8:157-66.
Yamashita H, Onishi H, Matsumoto Y, Murakami N, Matsuo Y, Nomiya T, et al. Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. Radiat Oncol. 2014;9:112.
Sun J, Zhang T, Wang J, Li W, Zhang A, He W, et al. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm). BMC Canc. 2019;19:846.
Murray LJ, Sykes J, Brierley J, Kim JJ, Wong RKS, Ringash J, et al. Baseline albumin-bilirubin (ALBI) score in western patients with hepatocellular carcinoma treated with stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys. 2018;101:900-9.
Su T-S, Yang H-M, Zhou Y, Huang Y, Liang P, Cheng T, et al. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. Radiat Oncol. 2019;14:50.
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2014;33:550-8.
Lo C-H, Liu M-Y, Lee M-S, Yang J-F, Jen Y-M, Lin C-S, et al. Comparison between child-turcotte-pugh and albumin-bilirubin scores in assessing the prognosis of hepatocellular carcinoma after stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;99:145-52.
Ohkoshi-Yamada M, Kamimura K, Shibata O, Morita S, Kaidu M, Nakano T, et al. Efficacy and safety of the radiotherapy for liver cancer: assessment of local controllability and its role in multidisciplinary therapy. Cancers. 2020;12:2955.
Hardy-Abeloos C, Lazarev S, Ru M, Kim E, Fischman A, Moshier E, et al. Safety and efficacy of liver stereotactic body radiation therapy for hepatocellular carcinoma after segmental transarterial radioembolization. Int J Radiat Oncol Biol Phys. 2019;105:968-76.
Jeong Y, Jung J, Cho B, Kwak J, Jeong C, Kim JH, et al. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Canc. 2018;18:416.
Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage. JAMA Oncol. 2018;4:40-7.
Teraoka Y, Kimura T, Aikata H, Daijo K, Osawa M, Honda F, et al. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma. Hepatol Res. 2018;48:193-204.
Liu HY, Lee Y, McLean K, Leggett D, Fawcett J, Mott R, et al. Efficacy and toxicity of stereotactic body radiotherapy for early to advanced stage hepatocellular carcinoma - initial experience from an Australian liver cancer service. Clin Oncol. 2020;32(10):e194-e202.
Gargett M, Haddad C, Kneebone A, Booth JT, Hardcastle N. Clinical impact of removing respiratory motion during liver SABR. Radiat Oncol. 2019;14:93.
Molinelli S, de Pooter J, Romero AM, Wunderink W, Cattaneo M, Calandrino R, et al. Simultaneous tumour dose escalation and liver sparing in Stereotactic Body Radiation Therapy (SBRT) for liver tumours due to CTV-to-PTV margin reduction. Radiother Oncol. 2008;87:432-8.
Bibault J-E, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PloS One. 2013;8:e77472.
Jang WI, Kim M-S, Bae SH, Cho CK, Yoo HJ, Seo YS, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol. 2013;8:250.
Shirato H, Oita M, Fujita K, Watanabe Y, Miyasaka K. Feasibility of synchronization of real-time tumor-tracking radiotherapy and intensity-modulated radiotherapy from viewpoint of excessive dose from fluoroscopy. Int J Radiat Oncol Biol Phys. 2004;60:335-41.